GenEdit

·Founded 2016

Overview

GenEdit develops next-generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery. GenEdit has developed a novel and unique, non-viral system for CRISPR/Cas9 delivery. The position focuses on the design, testing of new Cas9 delivery vehicles.

Get the full list of 54,000+ investors

GenEdit and every other firm and angel in the database — as one spreadsheet you keep.

$19one-time payment · no subscription
  • All 54,000+ investors — VC firms, private equity, family offices and angels
  • The key person to contact at each one, with their job title
  • Their work email address
  • Their phone number
  • Their LinkedIn profile
  • Delivered as a single .xlsx file — download it as many times as you like
Get the full list — $19 → One payment. No seats, no credits, no expiry. Already bought it? Sign in to download it again — no second payment.

Every profile on this site is one row of the file, with the contact details masked — browse a few before you buy.

Frequently asked questions about GenEdit

Who are the partners at GenEdit?

Team members listed for GenEdit include Kunwoo Lee (Chief Executive Officer & Co-founder) and Dong Kim (Chief Business Officer).

How do I contact GenEdit?

GenEdit's contact details are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.

Last updated · Source: ConnectSafely investor database